Kelly Hallowell

Exciting to see guidelines with a simplification of classifications as well as discussion of the importance of both patient and local resistance patterns!

Gilead Expands Global Access to Lenacapavir With New HIV Prevention Partnership Gilead Sciences has partnered with the Global Fund to supply up to 2 million doses of its long-acting HIV prevention drug, lenacapavir, to low and lower-middle income countries.

Perhaps a small piece of hopeful news? There is no benefit to a highly effective drugs if we can't get it to the people who need it.

New to this space! I'm an adult infectious diseases fellow interested in STIs and medical education. Here to learn all your clinical pearls and maybe a share a few of my own.